SAN FRANCISCO, Mar 09, 2010 (BUSINESS WIRE) -- Urigen Pharmaceuticals, Inc. (OTCBB:URGP), a specialty pharmaceutical
company focused on the development of treatments for urological
disorders and pain, announced today that video of the recent
presentation made by Prof. Lowell Parsons in Atlanta on February 25th,
2010 is now available at www.urigen.com.
C. Lowell Parsons, M.D., a director of Urigen, is a leader in medical
research into the causes and treatment of interstitial cystitis, which
is a painful bladder syndrome with typical cystoscopic and/or
histological features in the absence of infection or other pathology,
and has published over 200 scientific articles and book chapters in this
area describing his work. Dr. Parsons received his M.D. degree from the
Yale University School of Medicine in New Haven, CT, in 1970. After
completing his medical internship at Yale in 1971, Dr. Parsons spent two
years as a staff associate in the Laboratory of Microbiology at the
National Institutes of Health in Bethesda, Maryland. He then completed
his urology residency training at the Hospital of the University of
Pennsylvania in Philadelphia, Pennsylvania, in 1977. Dr. Parsons joined
the Division of Urology faculty at the University of California, San
Diego, in 1977 as assistant professor. He served as Chief of Urology at
the UCSD-affiliated Veterans Affairs Medical Center in La Jolla from
1977 to 1985. Since 1988, he has been Professor of Surgery/Urology.
About Urigen Pharmaceuticals, Inc.
Urigen Pharmaceuticals, Inc. is a specialty pharmaceutical company
dedicated to the development and commercialization of therapeutic
products for urological disorders. Urigen's two lead programs target
significant unmet medical needs and major market opportunities in
urology. Urigen's URG101, a proprietary combination of approved drugs
that is instilled into the bladder, targets painful bladder syndrome,
which affects approximately 10.5 million men and women in North America.
Urigen's URG301, a proprietary dosage form of an approved drug that is
locally delivered to control urinary urgency, targets acute urgency in
females diagnosed with an overactive bladder, another major unmet need
that is insufficiently managed by presently available overactive bladder
drugs. For further information, please visit Urigen's website at http://www.urigen.com.
Forward-Looking Statement
This press release may contain forward-looking statements. These
statements may be identified by the use of forward-looking terminology
such as "anticipate," "believe," "continue," "could," "estimate,"
"expect," "intend," "may," "might," "plan," "potential," "predict,"
"should," or "will," or the negative thereof or other variations thereon
or comparable terminology. Urigen has based these forward-looking
statements on current expectations, assumptions, estimates and
projections. While Urigen believes that these expectations, assumptions,
estimates and projections are reasonable, such forward-looking
statements are only predictions and involve known and unknown risks and
uncertainties, many of which are beyond its control. Given these risks
and uncertainties, investors and security holders are cautioned not to
place undue reliance on such forward-looking statements. Urigen does not
undertake any obligation to update any such statements or to publicly
announce the results of any revisions to any such statements to reflect
future events or developments.
SOURCE: Urigen Pharmaceuticals, Inc.
Urigen Pharmaceuticals, Inc.
William J. Garner, MD, 415-781-0350
Chief Executive Officer
http://www.urigen.com
